Pipeline Preview (November 2006)

News
Article

Lisdexamfetamine (NRP104, Shire/New River Pharmaceuticals) for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD)

Approvable designations

Fast-track designations

Orphan drug designations

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.